Indica Labs HALO AI vs Proscia Concentriq
Proscia has the stronger security paper trail. It announced SOC 2 Type II in December 2025, has held ISO 27001 since October 2023 and also holds ISO 13485. Indica's SOC 2, HIPAA and HITRUST status is not stated, so for a hospital that requires a SOC 2 Type II report on day one, Indica is the one to cross off. Concentriq AP-Dx holds 510(k) clearances from February 2024 and August 2026, the second adding the Leica Aperio GT 450 DX, cloud deployment and a change-control plan. Indica is the pick for a translational group that wants train-by-example segmentation on brightfield and fluorescence slides, or a European lab that wants HALO Prostate AI under CE-IVD. Its HALO AP Dx clearances name the Aperio GT 450 DX and the Hamamatsu S360MD. Agilent's agreement to acquire Proscia for up to $270M, announced October 13, 2026, has not closed and is expected to close early in Agilent's fiscal 2027.
Pathology · Reviewed November 1, 2026
Indica Labs HALO AI
by Indica Labs
HALO image analysis and AI for pathology research, plus HALO AP Dx (FDA-cleared) and HALO Prostate AI (CE-IVD) for clinical use.
Proscia Concentriq
by Proscia
Concentriq pathology platform for clinical labs and biopharma: image management, case review and AI apps, with FDA-cleared AP-Dx for primary diagnosis.
When to pick each one
Indica Labs HALO AI
- HALO AP Dx cleared with two named scanners
- HALO Prostate AI is CE-IVD marked
- Segmentation and phenotyping for fluorescence slides
Proscia Concentriq
- SOC 2 Type II announced December 2025
- Concentriq AP-Dx holds two FDA 510(k) clearances
- Vendor reports Best in KLAS 2026
Score
Each row shows points earned of points available under the published rubric.
Indica Labs HALO AI
33of 100
Proscia Concentriq
40of 100
| Dimension | Indica Labs HALO AI | Proscia Concentriq | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 6 / 10 | -6 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 0 / 21 | 0 / 21 | 0 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 0 / 7.8 | 0 |
| Funding & adoption signal | 8.4 / 12 | 8.4 / 12 | 0 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 0 / 6 | 0 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
Indica Labs HALO AI
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Proscia Concentriq
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Demo request only. |
Evidence
Indica Labs HALO AI
FDA decisions
K252762 (opens in new tab)510(k)2025-11-25
HALO AP Dx
K232833 (opens in new tab)510(k)2024-05-07
HALO AP Dx
Proscia Concentriq
FDA decisions
K261380 (opens in new tab)510(k)2026-08-05
Concentriq AP-Dx
K230839 (opens in new tab)510(k)2024-02-08
Concentriq Dx (marketed as Concentriq AP-Dx)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Indica Labs HALO AI | Proscia Concentriq |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | n/a | n/a |
| HQ | n/a | n/a |
Scroll horizontally to see both columns.
Common questions
Open the full pathology comparison
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.